ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1770

Recognition of Citrullinated and Carbamylated Proteins by Human Antibodies: Specificity, Cross-Reactivity and the “AMC-Senshu” Method

Jing Shi1, George Janssen2, Peter van Veelen2, Janwouter Drijfhout2, Antony Cerami3, Tom Huizinga4, Leendert A. Trouw5 and René E.M. Toes4, 1Rheumatology, LUMC, Leiden, Netherlands, 2Immunohematology and Bloodbank, LUMC, Leiden, Netherlands, 3Nephrology, LUMC, Leiden, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Rheumatology, Leiden University Medical Centre, Leiden, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, autoantibodies, citrulline and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti-citrullinated protein antibodies (ACPA) play an important role in the diagnosis and prognosis of Rheumatoid Arthritis (RA). The Anti-Modified Citrulline (AMC) (‘Senshu’) method is the most frequently used method to detect citrullinated proteins. Recently, we identified antibodies against carbamylated proteins (anti-CarP) and wished to know whether the ‘AMC-Senshu’ method could discriminate citrullinated and carbamylated proteins. More importantly, we also wished to know to what degree human autoantibodies can discriminate between these two modifications.

Methods:

We analyzed the reactivity of the ‘AMC-Senshu’ method and selected sera of RA patients on western blots targeting citrullinated, carbamylated or non-modified Fetal Calf Serum (FCS) and Fibrinogen (Fib). The levels of ACPA and anti-CarP antibodies in sera before and after ACPA depletion were compared and potential cross-reactivity analysed.

Results:

The ‘AMC-Senshu’ method strongly stained both citrullinated and carbamylated FCS and as well as citrullinated and carbamylated Fib but not the non-modified counterparts. This indicates that this method can not discriminate between these two modifications. Using patient sera we demonstrate that autoantibodies present in human serum can be specific for either carbamylated Fib or citrullinated Fib. In addition many RA patients can be double positive for both reactivities. To analyze if these patients are double positive because of cross-reactivity or because they contain two antibody families we used ACPA depletion columns to deplete all ACPA followed by analysis of ACPA levels and anti-CarP levels. After ACPA depletion, more than 98% of ACPA in the sera were depleted while more than half of anti-CarP antibodies remained in the flow through in 5 out of 7 samples tested. These data indicate that part, but not all anti-CarP antibodies are cross-reactive to citrullinated epitopes.

Conclusion:

In conclusion, the ‘AMC-Senshu’ method identifies both citrullinated and carbamylated proteins. In contrast human autoantibodies can discriminate between these two modifications indicating the presence of two separate families of autoantibodies, one directed against citrullinated protein and one directed against carbamylated proteins with a limited degree of cross-reactivity.

Disclosure: These studies were financially supported by Janssen Biologics BV, (Johnson & Johnson)


Disclosure:

J. Shi,
None;

G. Janssen,
None;

P. van Veelen,
None;

J. Drijfhout,
None;

A. Cerami,
None;

T. Huizinga,
None;

L. A. Trouw,
None;

R. E. M. Toes,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/recognition-of-citrullinated-and-carbamylated-proteins-by-human-antibodies-specificity-cross-reactivity-and-the-amc-senshu-method/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology